aTyr Pharma initiated with an Outperform at Leerink
Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...
ebroadsheet12h
‘A Serious Risk, Particularly to the Most Vulnerable’
Ending funding for ongoing studies will amount to a denial of the kind of care that sick responders and survivors need and ...